Onchocerciasis / River Blindness Lecture notes and 707 free access articles

Onchocerciasis also known as river blindness and Robles' disease, is a parasitic disease caused by infection by Onchocerca volvulus, a nematode. Onchocerciasis is the world's second-leading infectious cause of blindness.

River Blindness/ Onchocerciasis
Lawrence O. Gostin
http://www.pitt.edu/

Vector control
http://www.striepen.uga.edu/

CHALLENGING HEALTH PROBLEMS -WESTERN SUDAN
SULAIMAN, S. M.
http://www.pitt.edu

Blindness
Ines Serrano MD, Evan Waxman MD PHD
http://www.pitt.edu/

Ophthalmic Epidemiology
Michael B. Gorin, M.D. Ph.D.
http://www.pitt.edu/

Tropical Ophthalmology
Dr. Steve Waller
http://www.pitt.edu/
http://www.pitt.edu/

onchocerciasis
http://www.striepen.uga.edu/

River Blindness
http://courses.bio.unc.edu/

A Brief overview of Vector-Borne IIlness
Jill Gallin
http://www.columbia.edu/

Black-Flies, Biting Midges and Sandflies
http://www.uwyo.edu/

DNA barcoding for disease vectors
Daniel Adjei Boakye
http://barcoding.si.edu/

Lymphatic Filariasis / Elephantiasis Loiasis Onchocerciasis (river blindness)
Wafa Menawi
http://elearning.najah.edu/

Climate Change and Vector-Borne Disease
Durland Fish, Ph.D.
http://publichealth.yale.edu/

Use of GIS for Decision Making in the Onchocerciasis Control Program in West Africa
Alexander Coles
http://www.payson.tulane.edu/

Towards an ontology of vector-borne diseases
http://ontology.buffalo.edu/

The World of Parasites: A brief overview of the gruesome lives of parasites
Maya Merritt and Mindy Johnson
http://cipm.ncsu.edu

Neglected Tropical Diseases
Amy Kapczynski
http://gspp.berkeley.edu/

707 Published scholarly articles free access

1. Oligonucleotide Based Magnetic Bead Capture of Onchocerca volvulus DNA for PCR Pool Screening of Vector Black Flies.
2. [Evaluation on implementation of the African programme for onchocerciasis control in Nigeria].
3. Autophagy regulates Wolbachia populations across diverse symbiotic associations.
4. Empowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria and Uganda.
5. A research agenda for helminth diseases of humans: the problem of helminthiases.
6. A research agenda for helminth diseases of humans: intervention for control and elimination.
7. Human ocular onchocerciasis: further evidence on the zoonotic role of Onchocerca lupi.
8. Density-dependent mortality of the human host in onchocerciasis: relationships between microfilarial load and excess mortality.
9. Implementing preventive chemotherapy through an integrated National Neglected Tropical Disease Control Program in Mali.
10. Long term impact of large scale community-directed delivery of doxycycline for the treatment of onchocerciasis.
11. Immunization with L. sigmodontis microfilariae reduces peripheral microfilaraemia after challenge infection by inhibition of filarial embryogenesis.
12. Significant association between epilepsy and presence of onchocercal nodules: case-control study in Cameroon.
13. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
14. Validation of the rapid assessment procedure for loiasis (RAPLOA) in the democratic republic of Congo.
15. Multiple filarial species microfilaraemia: a comparative study of areas with endemic and sporadic onchocerciasis.
16. Nodding syndrome - South Sudan, 2011.
17. Prevalence of onchocerciasis in the Fundong Health District, Cameroon after 6 years of continuous community-directed treatment with ivermectin.
18. An insight into the sialome of Simulium guianense (DIPTERA:SIMulIIDAE), the main vector of River Blindness Disease in Brazil.
19. Neglected tropical diseases and the millennium development goals: why the "other diseases" matter: reality versus rhetoric.
20. African Programme for Onchocerciasis Control: meeting of national task forces, September 2011.
21. Ocular onchocerciasis: current management and future prospects.
22. The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji.
23. Onchocerciasis in the Americas: from arrival to (near) elimination.
24. InterAmerican Conference on Onchocerciasis, 2010: progress towards eliminating river blindness in the WHO Region of the Americas.
25. InterAmerican Conference on Onchocerciasis, 2010: progress towards eliminating river blindness in the WHO Region of the Americas.
26. Lymphatic filariasis in the Democratic Republic of Congo; micro-stratification overlap mapping (MOM) as a prerequisite for control and surveillance.
27. Rapid molecular assays for specific detection and quantitation of Loa loa microfilaremia.
28. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women.
29. Meeting of the International Task Force for Disease Eradication, April 2011.
30. Compliance with eight years of annual ivermectin treatment of onchocerciasis in Cameroon and Nigeria.
31. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA).
32. River blindness: an old disease on the brink of elimination and control.
33. Drawing and interpreting data: Children's impressions of onchocerciasis and community-directed treatment with ivermectin (CDTI) in four onchocerciasis endemic countries in Africa.
34. Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs.
35. Polymerase chain reaction pool screening used to compare prevalence of infective black flies in two onchocerciasis foci in northern Sudan.
36. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus.
37. Zoonotic helminths affecting the human eye.
38. Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa.
39. Elimination of neglected diseases in latin america and the Caribbean: a mapping of selected diseases.
40. Ivermectin, 'wonder drug' from Japan: the human use perspective.
41. Information for onchocerciasis control.
42. The applications of model-based geostatistics in helminth epidemiology and control.
43. Onchocerciasis.
44. Description of the parasite Wucheria bancrofti microfilariae identified in follicular fluid following transvaginal oocyte retrieval.
45. Gender-associated genes in filarial nematodes are important for reproduction and potential intervention targets.
46. Primary motives for demand of ivermectin drug in mass distribution programmes to control onchocerciasis.
47. Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy.
48. Skin Diseases.
49. Case report: First evidence of human zoonotic infection by Onchocerca lupi (Spirurida, Onchocercidae).
50. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale.
51. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda.
52. Social sciences research in neglected tropical diseases 2: A bibliographic analysis.
53. Perception and attitude of people toward onchocerciasis (river blindness) in South Western Nigeria.
54. A worm's best friend: recruitment of neutrophils by Wolbachia confounds eosinophil degranulation against the filarial nematode Onchocerca ochengi.
55. Mass drug administration of ivermectin in south-eastern Senegal reduces the survivorship of wild-caught, blood fed malaria vectors.
56. Geographical distribution of intestinal schistosomiasis and soil-transmitted helminthiasis and preventive chemotherapy strategies in Sierra Leone.
57. Emergence of Onchocerca volvulus from skin mimicking Dracunculiasis medinensis.
58. Long-term periodic anthelmintic treatments are associated with increased allergen skin reactivity.
59. Control of neglected tropical diseases needs a long-term commitment.
60. Selective activity of extracts of Margaritaria discoidea and Homalium africanum on Onchocerca ochengi.
61. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis.
62. Lipoprotein biosynthesis as a target for anti-Wolbachia treatment of filarial nematodes.
63. Biting behaviour of Simulium damnosum complex and Onchocerca volvulus infection along the Osun River, Southwest Nigeria.
64. Hyperendemicity of onchocerciasis in ovia northeast local government area, edo state, Nigeria.
65. Induction of immunoglobulin G4 in human filariasis: an indicator of immunoregulation.
66. Onchocerca armillata contains the endosymbiotic bacterium Wolbachia and elicits a limited inflammatory response.
67. Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths.
68. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
69. The Wolbachia endosymbiont as an anti-filarial nematode target.
70. Report from the 2009 Inter-American Conference on Onchocerciasis: progress towards eliminating river blindness in the Region of the Americas.
71. Neglected tropical diseases outside the tropics.
72. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells.
73. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
74. Low levels of transforming growth factor-beta (TGF-beta) and reduced suppression of Th2-mediated inflammation in hyperreactive human onchocerciasis.
75. Community-directed interventions for priority health problems in Africa: results of a multicountry study.
76. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa.
77. Analysis of the mdr-1 gene in patients co-infected with Onchocerca volvulus and Loa loa who experienced a post-ivermectin serious adverse event.
78. Interruption of transmission of Onchocerca volvulus in the Oaxaca focus, Mexico.
79. Lack of active Onchocerca volvulus transmission in the northern Chiapas focus of Mexico.
80. The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors.
81. Factors associated with compliance with community directed treatment with ivermectin for onchocerciasis control in Southwestern Ethiopia.
82. Immunohistology of ectopic secondary lymph follicles in subcutaneous nodules from patients with hyperreactive onchocerciasis (sowda).
83. Onchocerciasis in the upper imo river basin, Nigeria: prevalence and comparative study of waist and shoulder snips from mesoendemic communities.
84. Anticoagulant activity in salivary gland homogenates of Thyrsopelma guianense (Diptera: Simuliidae), the primary vector of onchocerciasis in the Brazilian Amazon.
85. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial.
86. Does onchocerciasis transmission take place in hypoendemic areas? a study from the North Region of Cameroon.
87. A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.
88. Immunohistological studies on neoplasms of female and male Onchocerca volvulus: filarial origin and absence of Wolbachia from tumor cells.
89. Reframing critical needs in vector biology and management of vector-borne disease.
90. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis.
91. Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting.
92. African Programme for Onchocerciasis Control - report of the sixth meeting of national task forces, October 2009.
93. Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human onchocerca nodule.
94. Monitoring ivermectin distributors involved in integrated health care services through community-directed interventions--a comparison of Cameroon and Uganda experiences over a period of three years (2004-2006).
95. [River blindness can be eliminated].
96. Preliminary study on temporal variations in biting activity of Simulium damnosum s.l. in Abeokuta North LGA, Ogun State Nigeria.
97. Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure.
98. Neglected tropical diseases in Brazil.
99. Picture this...Onchocerciasis.
100. Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.
101. Onchocerciasis (river blindness). Report from the eighteenth InterAmerican Conference on Onchocerciasis, November 2008.
102. Onchocerciasis: elimination is feasible.
103. Newly acquired Onchocerca volvulus filariae after doxycycline treatment.
104. Community-directed delivery of doxycycline for the treatment of onchocerciasis in areas of co-endemicity with loiasis in Cameroon.
105. Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden.
106. Exposure of seasonal migrant workers to Onchocerca volvulus on coffee plantations in Guatemala.
107. Laboratory diagnosis of infections due to blood and tissue parasites.
108. Prospects for the control of neglected tropical diseases by mass drug administration.
109. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.
110. The heme biosynthetic pathway of the obligate Wolbachia endosymbiont of Brugia malayi as a potential anti-filarial drug target.
111. Worrisome outbreak of river blindness in northern Uganda.
112. Epilepsy in onchocerciasis endemic areas: systematic review and meta-analysis of population-based surveys.
113. Rapid mapping of schistosomiasis and other neglected tropical diseases in the context of integrated control programmes in Africa.
114. A four-antigen mixture for rapid assessment of Onchocerca volvulus infection.
115. Nigeria's war on terror: fighting dracunculiasis, onchocerciasis, lymphatic filariasis, and schistosomiasis at the grassroots.
116. Cardiocladius oliffi (Diptera: Chironomidae) as a potential biological control agent against Simulium squamosum (Diptera: Simuliidae).
117. Successful interruption of transmission of Onchocerca volvulus in the Escuintla-Guatemala focus, Guatemala.
118. Gamma interferon and interleukin-1 receptor 1 regulate neutrophil recruitment to the corneal stroma in a murine model of Onchocerca volvulus keratitis.
119. Onchocerciasis Control: Vision for the Future from a Ghanian perspective.
120. Immunoglobulin kappa chain locus on chromosome 2p12 and onchocerciasis.
121. Onchocerciasis and trachoma control: what has changed in the past two decades?
122. Zoonotic filariasis in the Arabian Peninsula: autochthonous onchocerciasis and dirofilariasis.
123. Onchocerciasis, cysticercosis, and epilepsy.
124. The global programme to eliminate lymphatic filariasis: health impact after 8 years.
125. The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination.
126. Impact of long-term treatment with ivermectin on the prevalence and intensity of soil-transmitted helminth infections.
127. Transmission dynamics of Simulium damnosum in rural communities of Akwa Ibom State, Nigeria.
128. African Programme for Onchocerciasis Control--report on task force meeting, July 2008.
129. Rapid suppression of Onchocerca volvulus transmission in two communities of the Southern Chiapas focus, Mexico, achieved by quarterly treatments with Mectizan.
130. Engaging the community: an interview with Uche Amazigo by Brown Hannah.
131. Report from the Inter-American Conference on Onchocerciasis, November 2007.
132. After a decade of annual dose mass ivermectin treatment in Cameroon and Uganda, onchocerciasis transmission continues.
133. UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle.
134. Human genetic resistance to Onchocerca volvulus: evidence for linkage to chromosome 2p from an autosome-wide scan.
135. Filarioid nematodes in cattle, sheep and horses in Finland.
136. Sir Nicholas Harold Lloyd Ridley: 10 July 1906 - 25 May 2001.
137. Of mice, cattle, and humans: the immunology and treatment of river blindness.
138. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis.
139. Population dynamics of onchocerca volvulus microfilariae in human host after six years of drug control.
140. Encephalopathy after ivermectin treatment in a patient infected with Loa loa and Plasmodium spp.
141. A Global Fund to Fight Neglected Tropical Diseases: is the G8 Hokkaido Toyako 2008 Summit ready?
142. A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.
143. Could neurocysticercosis be the cause of "onchocerciasis-associated" epileptic seizures?
144. Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study.
145. Onchocerca jakutensis filariasis in humans.
146. Evidence for suppression of Onchocerca volvulus transmission in the Oaxaca focus in Mexico.
147. Fc gamma RIIa (CD32) polymorphism and onchocercal skin disease: implications for the development of severe reactive onchodermatitis (ROD).
148. Contribution of migrant coffee labourers infected with Onchocerca volvulus to the maintenance of the microfilarial reservoir in an ivermectin-treated area of Mexico.
149. Oncocerchiasis: an imported case from the tropics.
150. Eliminating lymphatic filariasis, onchocerciasis, and schistosomiasis from the americas: breaking a historical legacy of slavery.
151. Measuring the burden of neglected tropical diseases: the global burden of disease framework.
152. Epidemiology and psycho-social aspects of onchocercal skin diseases in northeastern Nigeria.
153. Monitoring lymphatic filariasis interventions: Adult mosquito sampling, and improved PCR - based pool screening method for Wuchereria bancrofti infection in Anopheles mosquitoes.
154. Taxonomy and inventory of the cytospecies and cytotypes of the Simulium damnosum complex (Diptera: Simuliidae) in relation to onchocerciasis.
155. Mining predicted essential genes of Brugia malayi for nematode drug targets.
156. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.
157. A new voice for the poor.
158. Ivermectin resistance in Onchocerca volvulus: toward a genetic basis.
159. The future of onchocerciasis control in Africa.
160. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment.
161. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin.
162. Persistent and untreated tropical infectious diseases among Sudanese refugees in the United States.
163. Toll-like receptor 2 regulates CXC chemokine production and neutrophil recruitment to the cornea in Onchocerca volvulus/Wolbachia-induced keratitis.
164. Onchocerciasis (river blindness). Report from the sixteenth InterAmerican Conference on Onchocerciasis, Antigua Guatemala, Guatemala.
165. Elimination of Onchocercia volvulus transmission in the Santa Rosa focus of Guatemala.
166. WHO-based tropical disease research programme to focus on emerging diseases.
167. Meeting of the International Task Force for Disease Eradication--11 January 2007.
168. Impact of long-term treatment of onchocerciasis with ivermectin in Ecuador: potential for elimination of infection.
169. Mansonella streptocerca: another filarial worm in the skin in Western Uganda.
170. Community selection of ivermectin distributors.
171. Vision 2020: update on onchocerciasis.
172. Onchocerciasis: impact of interventions.
173. The maintenance and repair of ophthalmic surgical instruments: training at the eye clinic.
174. Detection of Onchocerca volvulus (Nematoda: Onchocercidae) infection in vectors from Amazonian Brazil following mass Mectizan distribution.
175. Prevalence and causes of blindness and visual impairment in Limbe urban area, South West Province, Cameroon.
176. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
177. Feasibility of measuring compliance to annual ivermectin treatment in the African Programme for Onchocerciasis Control.
178. Lack of resistance after re-exposure of cattle cured of Onchocerca ochengi infection with oxytetracycline.
179. Evaluation of the diethylcarbamazine patch to evaluate onchocerciasis endemicity in Central Africa.
180. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM.
181. The reliability of anterior segment lesions as indicators of onchocercal eye disease in Guatemala.
182. Recent updates on onchocerciasis: diagnosis and treatment.
183. Modeling targeted ivermectin treatment for controlling river blindness.
184. [Vector capacities of Similium damsnosum s.l and risk for Onchocerca volvulus transmission in Inga (Democratic Republic of Congo)].
185. Successful integration of insecticide-treated bed net distribution with mass drug administration in Central Nigeria.
186. The Mectizan Donation Program - highlights from 2005.
187. River blindness: a success story under threat?
188. Integration of mass drug administration programmes in Nigeria: The challenge of schistosomiasis.
189. Onchocerciasis (river blindness). Report from the fifteenth InterAmerican Conference on Onchocerciasis, Caracas, Venezuela.
190. Reduction in the prevalence and intensity of infection in Onchocerca volvulus microfilariae according to ethnicity and community after 8 years of ivermectin treatment on the island of Bioko, Equatorial Guinea.
191. Cytogenetic and PCR-based identification of S. damnosum "Nkusi J" as the anthropophilic blackfly in the Uluguru onchocerciasis focus in Tanzania.
192. Onchocercosis of an intervertebral joint capsule causing cervical vertebral stenotic myelopathy in a horse.
193. Field applicability of a rapid-format anti-Ov-16 antibody test for the assessment of onchocerciasis control measures in regions of endemicity.
194. Perception of blindness and blinding eye conditions in rural communities.
195. Large-scale entomologic assessment of Onchocerca volvulus transmission by poolscreen PCR in Mexico.
196. [Onchocerciasis: one way of living].
197. [Parasitic etiology of blood hypereosinophilia].
198. Consequences of vector behavior in epidemiology of onchocerciasis on the Firestone Rubber Plantation in Liberia.
199. Important experimental parameters for determining infection rates in arthropod vectors using pool screening approaches.
200. Global epidemiology, ecology and control of soil-transmitted helminth infections.
201. Vision 2020 and prevention of blindness: is it relevant or achievable in the modern era?
202. Prevalence and causes of blindness and visual impairment in Muyuka: a rural health district in South West Province, Cameroon.
203. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination.
204. The promise of wolbachia-targeted chemotherapy as a public health intervention for lymphatic filariasis and onchocerciasis.
205. Wolbachia- and Onchocerca volvulus-induced keratitis (river blindness) is dependent on myeloid differentiation factor 88.
206. Assessment of microfilarial loads in the skin of onchocerciasis patients after treatment with different regimens of doxycycline plus ivermectin.
207. Case records of the Massachusetts General Hospital. Case 39-2005. A 63-year-old woman with a positive serologic test for syphilis and persistent eosinophilia.
208. Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease.
209. Short report: impact of ivermectin community-level treatments on elimination of adult Onchocerca volvulus when individuals receive multiple treatments per year.
210. Protective immunity to the larval stages of onchocerca volvulus is dependent on Toll-like receptor 4.
211. Chemokines in onchocerciasis patients after a single dose of ivermectin.
212. Human infection patterns and heterogeneous exposure in river blindness.
213. Short communication: impact of long-term (14 years) bi-annual ivermectin treatment on Wuchereria bancrofti microfilaraemia.
214. Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species).
215. Status of forest onchocerciasis in the Lower Cross River basin, Nigeria: entomologic profile after five years of ivermectin intervention.
216. Repeated high doses of avermectins cause prolonged sterilisation, but do not kill, Onchocerca ochengi adult worms in African cattle.
217. Onchocerciasis diagnosed in Italy.
218. Mass ivermectin treatment for onchocerciasis: lack of evidence for collateral impact on transmission of Wuchereria bancrofti in areas of co-endemicity.
219. Onchocerciasis: a potential risk factor for glaucoma.
220. The order is rapidly fadin'.
221. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels.
222. Predictors of compliance with community-directed ivermectin treatment in Uganda: quantitative results.
223. Effect of repeated community-based ivermectin treatment on the intensity of onchocerciasis in Nigeria.
224. Combined Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis (REA) in Rain forest Villages of Cameroon.
225. Community-directed interventions strategy enhances efficient and effective integration of health care delivery and development activities in rural disadvantaged communities of Uganda.
226. Frequent detection of worm movements in onchocercal nodules by ultrasonography.
227. Development and evaluation of an antigen detection dipstick assay for the diagnosis of human onchocerciasis.
228. Whither onchocerciasis control in Africa?
229. Prevalence of antibodies to onchocerca volvulus in residents of Oaxaca, Mexico, treated for 10 years with ivermectin.
230. Structure of the major cytosolic glutathione S-transferase from the parasitic nematode Onchocerca volvulus.
231. Prevalence of parasitic diseases among nomadic Fulanis of south-eastern Nigeria.
232. Anti-desmoglein-1 antibodies in onchocerciasis, leishmaniasis and Chagas disease suggest a possible etiological link to Fogo selvagem.
233. Relevance of ex vivo blood lymphocyte assay for in vivo lymphocyte function.
234. The effects of long-term community level treatment with ivermectin (Mectizan) on adult Onchocerca volvulus in Latin America.
235. Blackflies (Diptera: Simuliidae) of Southern Guyana with keys for the identification of adults and pupae--a review.
236. Wolbachia-induced neutrophil activation in a mouse model of ocular onchocerciasis (river blindness).
237. The role of mathematical modeling in evidence-based malaria control.
238. Additional health and development activities for community-directed distributors of ivermectin: threat or opportunity for onchocerciasis control?
239. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda.
240. Mapping the distribution of Loa loa in Cameroon in support of the African Programme for Onchocerciasis Control.
241. Two new cytoforms of the Simulium damnosum complex (Diptera: Simuliidae) from Malawi and Tanzania and potential onchocerciasis vectors.
242. Genetic heterogeneity in Loa loa parasites from southern Cameroon: A preliminary study.
243. The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4.
244. A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State, Nigeria.
245. Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971-2002.
246. Impact of ivermectin on illness and disability associated with onchocerciasis.
247. The delivery of ivermectin (Mectizan).
248. Economic evaluation of Mectizan distribution.
249. Mectizan Donation Program: evaluation of a public-private partnership.
250. Eliminating onchocerciasis as a public health problem.
251. Research for control: the onchocerciasis experience.
252. Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project.
253. Programmatic and Communication Issues in Relation to Serious Adverse Events Following Ivermectin Treatment in areas Co-endemic for Onchocerciasis and Loiasis.
254. A Framework for Decision-Making for Mass Distribution of Mectizan(R) in Areas Endemic for Loa loa.
255. Ivermectin: does P-glycoprotein play a role in neurotoxicity?
256. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.
257. Clinical picture and outcome of Serious Adverse Events in the treatment of Onchocerciasis.
258. Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.
259. Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.
260. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases.
261. Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
262. Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan(R) treatment of onchocerciasis in Loa loa endemic areas.
263. Polymerase chain reaction monitoring of transmission of Onchocerca volvulus in two endemic states in Mexico.
264. [Retinal hemorrhages after ivermectin treatment for onchocerciasis in a patient with Loa loa microfilaremia].
265. Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis.
266. Global change and human vulnerability to vector-borne diseases.
267. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis.
268. Stemming the tide of river blindness: the early years of ivermectin.
269. Integrated community-directed treatment for the control of onchocerciasis, schistosomiasis and intestinal helminths infections in Uganda: advantages and disadvantages.
270. Treatment of co-infection with bancroftian filariasis and onchocerciasis: a safety and efficacy study of albendazole with ivermectin compared to treatment of single infection with bancroftian filariasis.
271. Progressive vision loss in a man from Cameroon.
272. Multicentre laboratory evaluation of Brugia Rapid dipstick test for detection of brugian filariasis.
273. Prediction of community prevalence of human onchocerciasis in the Amazonian onchocerciasis focus: Bayesian approach.
274. Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis.
275. Onchocerciasis (river blindness).
276. Onchocerciasis among Ethiopian immigrants in Israel.
277. Obligatory symbiotic Wolbachia endobacteria are absent from Loa loa.
278. Product R&D for neglected diseases. Twenty-seven years of WHO/TDR experiences with public-private partnerships.
279. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa.
280. [Onchocerciasis].
281. Human immune responses to infective stage larval-specific chitinase of filarial parasite, Onchocerca volvulus, Ov-CHI-1.
282. Entomological evaluation by pool screen polymerase chain reaction of Onchocerca volvulus transmission in Ecuador following mass Mectizan distribution.
283. Final report of the Conference on the eradicability of Onchocerciasis.
284. Immune responses directed against microfilariae correlate with severity of clinical onchodermatitis and treatment history.
285. Local knowledge and attitudes about onchocerciasis in Oji-River local government area of Enugu State, Nigeria.
286. Onchocerciasis.
287. Profile of eye lesions and vision loss: a cross-sectional study in Lusambo, a forest-savanna area hyperendemic for onchocerciasis in the Democratic Republic of Congo.
288. Transmission intensity and the patterns of Onchocerca volvulus infection in human communities.
289. Serum immunoglobulin G4 antibodies to the recombinant antigen, Ll-SXP-1, are highly specific for Loa loa infection.
290. Rapid assessment method for prevalence and intensity of Loa loa infection.
291. Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda.
292. Lymphatic filariasis elimination and schistosomiasis control in combination with onchocerciasis control in Nigeria.
293. Association of transient dermal mastocytosis and elevated plasma tryptase levels with development of adverse reactions after treatment of onchocerciasis with ivermectin.
294. History of human parasitology.
295. Validity of nodule palpation in a Simulium neavei-transmitted onchocerciasis area in Uganda.
296. Human onchocerciasis in Brazil: an overview.
297. Comparison between the skin snip test and simple dot blot assay as potential rapid assessment tools for Onchocerciasis in the postcontrol era in Ghana.
298. IL-4 and IL-13 regulation of ICAM-1 expression and eosinophil recruitment in Onchocerca volvulus keratitis.
299. Sensitive and specific serodiagnosis of onchocerciasis with recombinant hybrid proteins.
300. Eliminating onchocerciasis as a public health problem: the beginning of the end.
301. Can ivermectin mass treatments eliminate onchocerciasis in Africa?
302. Could antibiotics cure river blindness?
303. An internal control for the detection of Onchocerca volvulus DNA by PCR-ELISA and rapid detection of specific PCR products by DNA Detection Test Strips.
304. HIV infection and tropical parasitic diseases - deleterious interactions in both directions?
305. Good news on a tropical disease.
306. Ecdysteroids and oocyte development in the black fly Simulium vittatum.
307. Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity.
308. Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density.
309. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions.
310. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness.
311. Survey of blindness and visual impairment in Bioko, Equatorial Guinea.
312. Factors associated with coverage in community-directed treatment with ivermectin for onchocerciasis control in Oyo State, Nigeria.
313. Antigenic mimicry: Onchocerca volvulus antigen-specific T cells and ocular inflammation.
314. Onchocerca volvulus glycolytic enzyme fructose-1,6-bisphosphate aldolase as a target for a protective immune response in humans.
315. Macrofilaricides and onchocerciasis control, mathematical modelling of the prospects for elimination.
316. Structural analysis and antibody response to the extracellular glutathione S-transferases from Onchocerca volvulus.
317. [Parasitosis by Onchocerca volvulus].
318. Black flies (Diptera: Simuliidae) of French Guiana: cytotaxonomy and a preliminary list of species.
319. Community-based ivermectin therapy for onchocerciasis: comparison of three methods of dose assessment.
320. Combined benefits of annual mass treatment with ivermectin and cattle zooprophylaxis on the severity of human onchocerciasis in northern Cameroon.
321. The Carter Center's assistance to river blindness control programs: establishing treatment objectives and goals for monitoring ivermectin delivery systems on two continents.
322. Eliminating onchocerciasis after 14 years of vector control: a proved strategy.
323. Blindness in Africa: present situation and future needs.
324. A dominant role for Fc gamma receptors in antibody-dependent corneal inflammation.
325. Down-regulated lymphoproliferation coincides with parasite maturation and with the collapse of both gamma interferon and interleukin-4 responses in a bovine model of onchocerciasis.
326. Simulium cuasiexiguum, a new blackfly species (Diptera: Simuliidae) from the Minaçu area in the State of Goiás, Central Brazil.
327. Distinct roles for PECAM-1, ICAM-1, and VCAM-1 in recruitment of neutrophils and eosinophils to the cornea in ocular onchocerciasis (river blindness).
328. Paper chromatography hybridization: a rapid method for detection of Onchocerca volvulus DNA amplified by PCR.
329. Early human infection with Onchocerca volvulus is associated with an enhanced parasite-specific cellular immune response.
330. Hyperreactive onchocerciasis exhibits reduced arachidonate and linoleate levels in serum triglycerides.
331. Community-directed treatment of onchocerciasis with ivermectin in Takum, Nigeria.
332. Corneal blindness: a global perspective.
333. CXC chemokine receptor 2 but not C-C chemokine receptor 1 expression is essential for neutrophil recruitment to the cornea in helminth-mediated keratitis (river blindness).
334. Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis.
335. Use of the recombinant Onchocerca volvulus protein Ov20/OvS1 for the immunodiagnostic differentiation between onchocerciasis and mansonelliasis and for the characterization of hyperreactive onchocerciasis (sowda).
336. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure.
337. Onchocerca ochengi transmission dynamics and the correlation of O. ochengi microfilaria density in cattle with the transmission potential.
338. Development of a recombinant antigen vaccine against infection with the filarial worm Onchocerca volvulus.
339. A rapid-format antibody card test for diagnosis of onchocerciasis.
340. Impaired eosinophil recruitment to the cornea in P-selectin-deficient mice in Onchocerca volvulus keratitis (River blindness).
341. CD4(+) depletion selectively inhibits eosinophil recruitment to the cornea and abrogates Onchocerca volvulus keratitis (River blindness).
342. Distinct response kinetics of gamma interferon and interleukin-4 in bovine tuberculosis.
343. Looking forward to 20/20: a focus on the epidemiology of eye diseases.
344. The epidemiology of human hookworm infections in the southern region of Mali.
345. Macrofilaricidal activity of tetracycline against the filarial nematode Onchocerca ochengi: elimination of Wolbachia precedes worm death and suggests a dependent relationship.
346. Identification of potential vaccine and drug target candidates by expressed sequence tag analysis and immunoscreening of Onchocerca volvulus larval cDNA libraries.
347. Fine specificity of autoantibodies to calreticulin: epitope mapping and characterization.
348. Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift.
349. A health club for a community school in south-eastern Nigeria: influence on adult perception of onchocerciasis and compliance with community-based ivermectin therapy.
350. New species records for the blackfly (Diptera-simuliidae) fauna of Argentina with description of adults, pupa and larva of Simulium oyapockense s. l. And S. seriatum.
351. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens.
352. Treatment with ivermectin: what works in one community may not work in another.
353. The Simulium damnosum complex in western Uganda and its role as a vector of Onchocerca volvulus.
354. [Semi-annular pre-equatorial scleral ectasia in a patient with glaucoma and onchocerciasis].
355. Where health care has no access: the nomadic populations of sub-Saharan Africa.
356. Interleukin-12 modulates T-cell responses to microfilariae but fails to abrogate interleukin-5-dependent immunity in a mouse model of onchocerciasis.
357. Comparative analysis of glycosylated and nonglycosylated filarial homologues of the 20-kilodalton retinol binding protein from Onchocerca volvulus (Ov20).
358. Human onchocerciasis and tetanus vaccination: impact on the postvaccination antitetanus antibody response.
359. WHO celebrates triumph over river blindness.
360. An essential role for antibody in neutrophil and eosinophil recruitment to the cornea: B cell-deficient (microMT) mice fail to develop Th2-dependent, helminth-mediated keratitis.
361. Eotaxin expression in Onchocerca volvulus-induced dermatitis after topical application of diethylcarbamazine.
362. [Effect of Onchocerca volvulus infestation on plasma vitamin A concentration in school children in a rural region of Cameroon].
363. Onchocerciasis modulates the immune response to mycobacterial antigens.
364. Regulatory effects of Th1-type (IFN-gamma, IL-12) and Th2-type cytokines (IL-10, IL-13) on parasite-specific cellular responsiveness in Onchocerca volvulus-infected humans and exposed endemic controls.
365. Rapid assessment of onchocerciasis endemicity.
366. Temporal recruitment of neutrophils and eosinophils to the skin in a murine model for onchocercal dermatitis.
367. [Conjunctivitis and ocular parasitic diseases].
368. Prenatal immune priming in onchocerciasis-onchocerca volvulus-specific cellular responsiveness and cytokine production in newborns from infected mothers.
369. Analysis of renal function in onchocerciasis patients before and after therapy.
370. Induction of histamine release in parasitized individuals by somatic and cuticular antigens from Onchocerca volvulus.
371. Pathogenesis of onchocercal keratitis (River blindness).
372. Population biology of human onchocerciasis.
373. Distribution of the blinding and nonblinding strains of Onchocerca volvulus in Nigeria.
374. Comparison of serological and parasitological assessments of Onchocerca volvulus transmission after 7 years of mass ivermectin treatment in Mexico.
375. Independent evaluation of onchocerciasis rapid assessment methods in Benue State, Nigeria.
376. Onchocerciasis and epilepsy: a matched case-control study in the Central African Republic.
377. Onchocerciasis.
378. Candidate parasitic diseases.
379. Pool screen polymerase chain reaction for estimating the prevalence of Onchocerca volvulus infection in Simulium damnosum sensu lato: results of a field trial in an area subject to successful vector control.
380. Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin.
381. Geographical determinants of onchocerciasis transmission in a forest/savannah transition zone : two villages of the mbam focus
382. [Geographic determinants of onchocerciasis transmission in a forest-savannah transition zone: an example of 2 villages of the Mbam focus (central region, Cameroon)].
383. Incorporating gender in the anthropology of infectious diseases.
384. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial.
385. Is apoptosis involved in mechanisms to eliminate Onchocerca ochengi during Simulium damnosum s.l. immune response?
386. A cocktail of recombinant Onchocerca volvulus antigens for serologic diagnosis with the potential to predict the endemicity of onchocerciasis infection.
387. Ivermectin influence on the mast cell activity in nodules of onchocerciasis patients.
388. Treatment of onchocerciasis with ivermectin (Province of Bururi, Burundi): parasitologic and clinical evaluation of different periodicities of treatment.
389. Onchocerciasis and Chagas' disease control: the evolution of control via applied research through changing development scenarios.
390. Willingness to pay for community-based ivermectin distribution: a study of three onchocerciasis-endemic communities in Nigeria.
391. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10.
392. Prevalence of Onchocerca volvulus nodules in the Sankuru River Valley, Democratic Republic of the Congo, and reliability of verbal assessment as a method for determining prevalence.
393. Blue-yellow colour vision in an onchocercal area of northern Nigeria.
394. [Ten Years of Mectizan in Africa: Partnerships for Long-Term Success. Conference proceedings. Mali, November 4-5, 1997].
395. [Partnerships for prolonged success in onchocerciasis control in Guinea].
396. Detection of the filarial parasite Mansonella streptocerca in skin biopsies by a nested polymerase chain reaction-based assay.
397. Detection of Onchocerca volvulus infection by O-150 polymerase chain reaction analysis of skin scratches.
398. [Progress in the control of world blindness and future perspectives].
399. [Synthesis of the blindness situation in the countries of the Organization for Cooperation and Coordination in the Control of Major Endemic Diseases].
400. Tropomyosin implicated in host protective responses to microfilariae in onchocerciasis.
401. Chemotherapy for onchocerciasis: results of in vitro experiments with promising new compounds.
402. Novel, sensitive and low-cost diagnostic tests for 'river blindness'--detection of specific antigens in tears, urine and dermal fluid.
403. The role of eosinophils and neutrophils in helminth-induced keratitis.
404. IL-5-dependent immunity to microfilariae is independent of IL-4 in a mouse model of onchocerciasis.
405. Current status of onchocerciasis in Colombia.
406. [Indication of Mectizan in human medicine other than onchocerciasis].
407. [Distribution and treatment using ivermectin under community directives].
408. [The strategic role of information, education and communication in treatment programs using ivermectin (Mectizan) under community directives].
409. [Mectizan and onchocerciasis: 10 years of Mectizan in Africa, a partnership for prolonged success].
410. [Partnerships and distribution of Mectizan. Distribution of ivermectin in countries at war].
411. [Partnerships and distribution of Mectizan. Sector investment programs for an integrated approach to investment loans].
412. [Partnerships and the distribution of Mectizan. Ministries of health].
413. [Parnerships and the distribution of Mectizan. The example of the onchocerciasis control program].
414. [Improvement in the quality of life in rural Africa (AFRICARE) in the face of onchocerciasis in Chad (Mectizan donation program)].
415. [Partnerships and the distribution of Mectizan. The role of a non-governmental development organization in a country with endemic onchocerciasis].
416. [The placement of partnerships for Mectizan distribution systems].
417. [The Mectizan donation program in Gabon: progress and perspectives of distribution in the focus of onchocerciasis (1991-1997)].
418. [Onchocerciasis control program in Chad: the Mectizan donation].
419. [Onchocerciasis in Tanzania].
420. [Onchocerciasis in African countries not included in the onchocerciasis control program].
421. [The African onchocerciasis control program: essential characteristics].
422. [Onchocerciasis in West Africa. Strategies for mass treatment under community directives in Ghana].
423. [Onchocerciasis in the Ivory Coast].
424. [Onchocerciasis control in Senegal: evaluation of 10 years of control].
425. [The beginning of the OPC and the status of onchocerciasis in western Africa before control measures].
426. [The onchocerciasis control program in West Africa (OCP): essential characteristics].
427. [Contribution of mectizan to the control of onchocerciasis. Effect on transmission after 8 years of treatment].
428. [Contribution of mectizan to the control of onchocerciasis. Effect on transmission: evaluation of 9 years of treatment in West Africa].
429. [Contribution of mectizan to the control of onchocerciasis. Impact on ocular lesions].
430. [Onchocerciasis and the Mectizan donation program].
431. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.
432. Ivermectin distribution using community volunteers in Kabarole district, Uganda.
433. [Large dams, health and nutrition in Africa: beyond the controversy].
434. [Onchodermatitis (sowda) in patients in Yémen. Clinical and histologic course after treatment with ivermectin].
435. The Ov20 protein of the parasitic nematode Onchocerca volvulus. A structurally novel class of small helix-rich retinol-binding proteins.
436. Immunization with the cross-reactive antigens Ov39 from Onchocerca volvulus and hr44 from human retinal tissue induces ocular pathology and activates retinal microglia.
437. Differences in cytokine responses to Onchocerca volvulus extract and recombinant Ov33 and OvL3-1 proteins in exposed subjects with various parasitologic and clinical states.
438. Protective responses against skin-dwelling microfilariae of Onchocerca lienalis in severe combined immunodeficient mice.
439. Blindness and visual impairment in a region endemic for onchocerciasis in the Central African Republic.
440. Olecranon lesions caused by Onchocerca skrjabini in wild Japanese serows (Capricornis crispus).
441. Production of both IFN-gamma and IL-5 by Onchocerca volvulus S1 antigen-specific CD4+ T cells from putatively immune individuals.
442. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
443. Onchocerca volvulus: comparison of field collection methods for the preservation of parasite and vector samples for PCR analysis.
444. Required duration of combined annual ivermectin treatment and vector control in the Onchocerciasis Control Programme in west Africa.
445. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss.
446. Visual field constriction as a cause of blindness or visual impairment.
447. The novel cuticular collagen Ovcol-1 of Onchocerca volvulus is preferentially recognized by immunoglobulin G3 from putatively immune individuals.
448. RANTES in onchocerciasis: changes with ivermectin treatment.
449. In utero exposure to Onchocerca volvulus: relationship to subsequent infection intensity and cellular immune responsiveness.
450. Low-molecular-weight protein ligands from Onchocerca volvulus preferentially stimulate the human gammadelta T cell Vdelta1+ subset.
451. Maintaining compliance to ivermectin in communities in two West African countries.
452. Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy: cellular autoimmunity in onchocercal chorioretinopathy.
453. Immunoregulation in onchocerciasis: predominance of Th1-type responsiveness to low molecular weight antigens of Onchocerca volvulus in exposed individuals without microfilaridermia and clinical disease.
454. Immunoregulation in onchocerciasis: persons with ocular inflammatory disease produce a Th2-like response to Onchocerca volvulus antigen.
455. Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis.
456. Onchocerciasis in Ecuador: evolution of chorioretinopathy after amocarzine treatment.
457. Polymerase chain reaction-based assessment after macrofilaricidal therapy in Onchocerca volvulus infection.
458. Reactivity of various leishmanial antigens in a direct agglutination test and their value in differentiating post-kala azar dermal leishmaniasis from leprosy and other skin conditions.
459. Absence of cellular responses to a putative autoantigen in onchocercal chorioretinopathy. Cellular autoimmunity in onchocercal chorioretinopathy.
460. Ivermectin-induced immunopotentiation in onchocerciasis: recognition of selected antigens following a single dose of ivermectin.
461. Molecular cloning, expression, and localization of E1, an Onchocerca volvulus antigen with similarity to brain ankyrin.
462. Red-dot card test of the paracentral field as a screening test for optic nerve disease in onchocerciasis.
463. The prevalence of epilepsy follows the distribution of onchocerciasis in a west Ugandan focus.
464. Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.
465. Eye disease in an onchocerciasis-endemic area of the forest-savanna mosaic region of Nigeria.
466. Immunoglobulin kappa chain allotypes (KM) in onchocerciasis.
467. Knowledge, attitudes and practices during a community-level ivermectin distribution campaign in Guatemala.
468. Onchocerca volvulus larval antigen, OvB20, induces partial protection in a rodent model of onchocerciasis.
469. Interleukin 4 and T helper type 2 cells are required for development of experimental onchocercal keratitis (river blindness).
470. The treatment of scabies with ivermectin.
471. Human autoantibody to defensin: disease association with hyperreactive onchocerciasis (sowda).
472. Implementation of health initiatives during a cease-fire--Sudan, 1995.
473. [Health indicators of a population in an agro-industrial complex of southern Cameroon].
474. [The use of ivermectin in the control of onchocerciasis].
475. Onchocerciasis in Ecuador: ocular findings in Onchocerca volvulus infected individuals.
476. WHO's special programmes: undermining from above.
477. Impact of combined large-scale ivermectin distribution and vector control on transmission of Onchocerca volvulus in the Niger basin, Guinea.
478. Investigation of cross-reactions against Trichinella spiralis antigens by enzyme-linked immunosorbent assay and enzyme-linked immunoelectrotransfer blot assay in patients with various diseases.
479. Global data on blindness.
480. Socioeconomic consequences of blinding onchocerciasis in west Africa.
481. Evaluation of Onchocerca volvulus-specific IgG4 subclass serology as an index of onchocerciasis transmission potential of three Gabonese villages.
482. [Control of onchocerciasis vectors in West Africa: description of the logistics adapted for a large-scale public health program].
483. The World Health Organisation in Africa.
484. Blindness from uveitis in a hospital population in Sierra Leone.
485. Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis.
486. HLA-D alleles associated with generalized disease, localized disease, and putative immunity in Onchocerca volvulus infection.
487. Recent advances in tropical medicine.
488. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.
489. Prevalence of blindness and low vision of people over 30 years in the Wenchi district, Ghana, in relation to eye care programmes.
490. Influence of suramin on the expression of Fc receptors and other markers on human monocytes and U937 cells, and on their phagocytic properties.
491. Major retinal cell components recognized by onchocerciasis sera are associated with the cell surface and nucleoli.
492. The significance of blood levels of IgM, IgA, IgG and IgG subclasses in Sudanese visceral leishmaniasis patients.
493. Molecular cloning of an Onchocerca volvulus extracellular Cu-Zn superoxide dismutase.
494. Distribution and aetiology of blindness and visual impairment in mesoendemic onchocercal communities, Kaduna State, Nigeria. Kaduna Collaboration for Research on Onchocerciasis.
495. Setting the stage for onchocerciasis.
496. Neutrophil activation in ivermectin-treated onchocerciasis patients.
497. Immunologic cross-reactivity in the pathogenesis of ocular onchocerciasis.
498. Preliminary evaluation of recombinant Onchocerca volvulus antigens for serodiagnosis of onchocerciasis.
499. An immunohistochemical analysis of onchocercal nodules: evidence for an interaction between macrophage MRP8/MRP14 and adult Onchocerca volvulus.
500. Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases.
501. Visual loss in an onchocerciasis endemic community in Sierra Leone.
502. Ivermectin dose assessment without weighing scales.
503. Prevalence of depigmentation of the shins: a simple and cheap way to screen for severe endemic onchocerciasis in Africa.
504. [National entomological teams of the western extension zone of the Onchocerciasis Control Program (OCP) in west Africa from 1986 to 1990].
505. Cytological and isoenzyme analysis of the Bucay and Quevedo cytotypes of the Onchocerciasis vector Simulium exiguum (Diptera: Simuliidae) in Ecuador.
506. Diethylcarbamazine in the treatment of patients with onchocerciasis.
507. Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment.
508. Onchocerciasis in Ecuador: the situation in 1989.
509. Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus.
510. Onchocerciasis in members of an expedition to Cameroon: role of advice before travel and long term follow up.
511. The profile of IgG and IgG subclasses of onchocerciasis patients.
512. Suppression of human lymphocyte responses to specific and non-specific stimuli in human onchocerciasis.
513. Molecular cloning and characterization of recombinant parasite antigens for immunodiagnosis of onchocerciasis.
514. Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis.
515. Immunological crossreactivity between a cloned antigen of Onchocerca volvulus and a component of the retinal pigment epithelium.
516. Subtle early features of onchocerciasis in a European.
517. Immunoregulation in onchocerciasis. Functional and phenotypic abnormalities of lymphocyte subsets and changes with therapy.
518. Causes of blindness and visual handicap in the Central African Republic.
519. Experimental ocular onchocerciasis in cynomolgus monkeys. IV. Chorioretinitis elicited by Onchocerca volvulus microfilariae.
520. Ocular manifestations of onchocerciasis in a rain forest area of west Africa.
521. [Control of onchocerciasis with ivermectin: results of a mass campaign in northern Cameroon].
522. The risk and dynamics of onchocerciasis recrudescence after cessation of vector control.
523. Viability of adult Onchocerca volvulus after six 2-weekly doses of ivermectin.
524. Onchocerciasis distribution and severity in five West African countries.
525. Suramin affects DNA synthesis in HeLa cells by inhibition of DNA polymerases.
526. The influence of food on the pharmacokinetics of CGP 6140 (amocarzine) after oral administration of a 1200 mg single dose to patients with onchocerciasis.
527. Pharmacokinetics of CGP 6140 (amocarzine) after oral administration of single 100-1600 mg doses to patients with onchocerciasis.
528. Cell-mediated immunity against human retinal extract, S-antigen, and interphotoreceptor retinoid binding protein in onchocercal chorioretinopathy.
529. Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis.
530. Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans.
531. The predicted and observed decline in onchocerciasis infection during 14 years of successful control of Simulium spp. in west Africa.
532. Immunopathology of ocular onchocerciasis. I. Inflammatory cells infiltrating the anterior segment.
533. Community-based treatment of onchocerciasis with ivermectin: acceptability and early adverse reactions.
534. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials.
535. Unique recognition of a low molecular weight Onchocerca volvulus antigen by IgG3 antibodies in chronic hyper-reactive oncho-dermatitis (Sowda).
536. Experimental ocular onchocerciasis in cynomolgus monkeys. II. Chorioretinitis elicited by intravitreal Onchocerca lienalis microfilariae.
537. Biosystematics and distribution of simuliid vectors of human onchocerciasis in South America.
538. Molecular cloning of an immunodominant antigen of Onchocerca volvulus.
539. Effect of single-dose ivermectin therapy on human Onchocerca volvulus infection with onchocercal ocular involvement.
540. Isolation and characterization of expression cDNA clones encoding antigens of Onchocerca volvulus infective larvae.
541. Autoantibody induced by experimental Onchocerca infection. Effect of different routes of administration of microfilariae and of treatment with diethylcarbamazine citrate and ivermectin.
542. Characterization of an immunodominant Onchocerca volvulus antigen with patient sera and a monoclonal antibody.
543. Identification of vector species (Diptera:Simuliidae) of human onchocerciasis in the amazonia focus of Brazil and Venezuela.
544. Antibodies to tubulin in patients with parasitic infections.
545. Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis.
546. Drug treatment as an onchocerciasis control measure.
547. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin.
548. The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis.
549. Experimental ocular onchocerciasis in cynomolgus monkeys.
550. [The Brazilian focus of onchocerciasis: new observations in the areas of the Mucajaí and Catrimâni rivers, Territory of Roraima].
551. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area.
552. Human macrophages and T-lymphocyte subsets infiltrating nodules of Onchocerca volvulus.
553. Onchocerciasis now.
554. Common causes of blindness in Zaïre.
555. Social responsibilities in ophthalmology.
556. Eosinophilic cellulitis as a manifestation of onchocerciasis.
557. IgE production in vitro by peripheral blood mononuclear cells of patients with parasitic helminth infections.
558. Ophthalmology in developing countries.
559. [Treatment of onchocerciasis with low, increasing doses of suramin in hyperendemic communities of Western Africa: 2. Clinical parasitologic and ophthalmologic results in a zone where transmission is controlled].
560. Cost-effectiveness of blindness prevention by the Onchocerciasis Control Programme in Upper Volta.
561. Recent developments in the treatment of onchocerciasis.
562. My student elective. Along the White Nile.
563. Non-specific suppression of antigen-induced lymphocyte blastogenesis in Onchocerca volvulus infection in man.
564. Cutaneous onchocerciasis in the horse: five cases in southwestern british columbia.
565. [Incidence of blindness and its epidemiological aspects in a rural region of western Africa].
566. Detection of IgE antibodies in onchocerciasis. Possibility of using allergens from Dipetalonema viteae extracts that cross-react with allergenic determinants in crude extracts of Onchocerca volvulus.
567. An endemic disease survey of Bong County, Liberia.
568. Circulating antigen-antibody complexes in onchocerciasis.
569. IgE antibodies are more species-specific than IgG antibodies in human onchocerciasis and lymphatic filariasis.
570. Equine onchocerciasis: lesions in the nuchal ligament of midwestern U.S. horses.
571. Further trials of mebendazole and metrifonate in the treatment of onchocerciasis.
572. Clinical trials of amodiaquine in onchocerciasis.
573. Histochemical enzyme variation in Onchocerca volvulus microfilariae from rain-forest and Sudan-savanna areas of the Onchocerciasis Control Programme in West Africa.
574. The six diseases of WHO. Onchocerciasis.
575. Ocular changes with oral and transepidermal diethylcarbamazine therapy of onchocerciasis.
576. Simuliidae of Goiás state and the Federal District (Brasília). 1. A description of Simulium (Chirostilbia) dekeyseri, new species.
577. Mineralized onchocercal lesions resembling tuberculosis in cattle. Report of cases from meat inspection.
578. The immunology of filariasis. Scientific Working Group on Filariasis.
579. Living larva of Onchocerca volvulus.
580. Changes in visual function and in the posterior segment of the eye during treatment of onchocerciasis with diethylcarbamazine citrate.
581. Circulating immune complexes in onchocerciasis.
582. Analysis of the anticomplementary activity in sera of three African patients with parasitic and bacteriological infections.
583. [Latency period in onchocerciasis].
584. [Treatment of onchocerciasis in hyperendemic communities in West Africa with small, gradually increasing doses of suramin. 1. Parasitological results and ophthalmological surveillance in a region where transmission has not been interrupted].
585. A three-year follow-up of ocular onchocerciasis in an area of vector control.
586. Bovine and equine onchocerciasis in eastern North America with a discussion on cuticular morphology of Onchocerca spp. in cattle.
587. Treatment of onchocerciasis.
588. Lepromatous leprosy and onchocerciasis.
589. Tanzania Filariasis Project: a provocative day test with diethylcarbamazine for the detection of microfilariae of nocturnally periodic Wuchereria bancrofti in the blood.
590. Inflammatory reactions in onchocerciasis: a report on current knowledge and recommendations for further study.
591. Epidemiological aspects of intraocular pressure in an onchocerciasis endemic area.
592. [Epidemiologic status of onchocerciasis].
593. The risk of optic atrophy following suramin treatment of ocular onchocerciasis.
594. Bovine onchocerciasis caused by Onchocerca armillata and O. gutturosa.
595. Visual field defects in onchocerciasis.
596. Aspects of corneal changes in onchocerciasis.
597. Further studies on the treatment of ocular onchocerciasis with diethylcarbamazine and suramin.
598. Further observations on the relationship between ocular onchocerciasis and the head nodule, and on the possible benefit of nodulectomy.
599. Evaluation of microfilaricidal effects in the cornea from topically applied drugs in ocular onchocerciasis: Trials with levamisole and mebendazole.
600. Effects of various concentrations of diethylcarbamazine citrate applied as eye drops in ocular onchocerciasis, and the possibilities of improved therapy from continuous non-pulsed delivery.
601. Onchocerciasis--out of oubliette.
602. [Evolution of 9 years of ocular onchocerciasis in a village community of Western Africa].
603. [Complex of species of Simuliidae].
604. Ocular onchocerciasis.
605. Species complexes in the Simuliidae.
606. A simplified technique for counting onchocercal microfilariae in skin snips.
607. The problem of uveitis in Bendel State of Nigeria: experience in Benin City.
608. [Onchocerca cervicalis infection in Quebec: clinical signs and diagnostic methods].
609. Dangerous reactions to treatment of onchocerciasis with diethylcarbamazine.
610. The microfilarial load in the anterior segment of the eye. A parameter of intensity of onchocerciasis.
611. Preliminary studies on the histochemical differentiation of strains of Onchocerca volvulus microfilariae in Togo.
612. Droplet degeneration of the cornea in North Cameroon. Prevalence and clinical appearances.
613. Antigenic diversity among Onchocerca volvulus in Nigeria, and immunological differences between onchocerciasis in the savanna and forest of Cameroon.
614. Morphology of posterior segment lesions of the eye in patients with onchocerciasis.
615. Transmission in utero of microfilariae of Onchocerca volvulus.
616. [Attempt at a collective treatment with diethylcarbamazine in a village in the region of Bamako (Mali) where onchocerciasis is hyperendemic].
617. Intra-ocular pressure in onchocerciasis. Some preliminary results of a field evaluation.
618. Epidemiological studies on onchocerciasis by means of a new field technique.
619. A new technique for the determination of microfilarial densities in onchocerciasis.
620. Editorial: Onchocerciasis.
621. Onchocerciasis in Canada.
622. Letter: Onchocerciasis in Canada.
623. Editorial: Onchocerciasis--river blindness.
624. Onchocerciasis in Canada.
625. An evaluation of skin snip techniques used in the quantitative assessment of microfilarial densities of Onchocerca volvulus.
626. [(A method of evaluating microfilaria densities of Onchocerca volvulus Leuckart, 1893, in onchoceriasis patients. Assessment of microfilarial densities by site and levels of prevelance in skin biopsies; variations of microfilarial densities over a 24 hour period)].
627. A simple technique for maintaining Stimulium adults, including onchocerciasis vectors, under artificial conditions.
628. [Results of 2 eye examinations carried out with an interval of 6 years in 2 Upper Volta villages where onchocerciasis is endemic].
629. Letter: Living microfilariae of Onchocerca volvulus in the cornea.
630. A comparison of African and European serum levels of immunoglobulin E.
631. Kerato-uveal changes in leprosy and onchocerciasis: a question of immunity.
632. Ocular onchocerciasis in Malawi. A comparative study of 500 patients and 500 controls.
633. Mating, blood feeding, and oviposition of Simulium damnosum Theobald in the laboratory.
634. Impacted microfilaria in the lens capsule.
635. United States Naval Medical Research Units in Africa.
636. [A method of evaluating the density of the microfilaria of Onchocerca volvulus Leuckart, 1893 in patients with onchocerciasis: technic and reading time of skin biopsies].
637. Microfilaruria in onchocerciasis. A clinical and epidemiological follow-up study in the Republic of Chad.
638. Heterophile antibodies in Nigerian sera.
639. Ovicides in Stimulium control.
640. The effects of drugs on Onchocerca volvulus. 4. Trials of melarsonyl potassium.
641. Tumoral calcinosis--an unrecognized disease.
642. Prospects for the control of onchocerciasis in Africa with special reference to the Volta River basin.
643. The impact of insecticide-resistance on control of vectors and vector-borne diseases.
644. Artificial feeding of East African female Simuliidae (Diptera), including vectors of human onchocerciasis.
645. Onchocerciasis.
646. Artificial feeding of Simulium vectors of human and bovine onchoceriasis.
647. Reinfections with Onchocerca volvulus in cured patients exposed to continuing transmission.
648. The simulium control scheme at Abuja, Northern Nigeria, and its effect on the prevalence of onchocerciasis in the area.
649. Experiments on the chemoprophylaxis of Onchocerca volvulus infection.
650. The intake and transmissibility of Onchocerca volvulus microfilariae by Simulium damnosum fed on patients treated with Diethylcarbamazine, suramin or Mel W.
651. The effects of drugs on Onchocerca volvulus. 3. Trials of suramin at different dosages and a comparison of the brands Antrypol, Moranyl and Naganol.
652. The effects of drugs on Onchocerca volvulus. 2. The antimonial preparations TWSb and MSbE.
653. The effects of drugs on Onchocerca volvulus. 1. Methods of assessment, population dynamics of the parasite and the effects of diethylcarbamazine.
654. Onchocerciasis.
655. Onchocerciasis in Kenya 9, 11 and 18 years after elimination of the vector.
656. A method of rearing Simulium damnosum Theobald (Diptera; Simuliidae) under artificial conditions.
657. A review of the control of Simulium vectors of onchocerciasis.
658. Surgical pathology in the course of the Nile.
659. A simple laboratory method for testing the susceptibility of larvae of the Simulium neavei complex to insecticides.
660. [OPHTHALMOLOGICAL ASPECTS OF ONCHOCERCIASIS IN GUATEMALA AND WEST AFRICA].
661. Onchocerciasis.
662. Onchocerciasis.
663. ONCHOCERCIASIS IN BRITAIN.
664. [BIOLOGY AND ECOLOGY OF THE FEMALE OF SIMULIUM DAMNOSUM THEOBALD, 1903, AS A FUNCTION OF THE BIOCLIMATIC ZONES OF WEST AFRICA. INFLUENCE ON THE EPIDEMIOLOGY OF ONCHOCERCIASIS].
665. PESTICIDES: A CONTRIBUTION TO PUBLIC HEALTH.
666. A standard method of assessing microfilarial densities on onchocerciasis surveys.
667. The control of Simulium damnosum at Abuja, Northern Nigeria, 1955-60.
668. Simuliidae and their relation to human onchocerciasis in northern Venezuela.
669. Onchocerciasis and filariasis: Introduction.
670. OCULAR LESIONS OF ONCHOCERCIASIS.
671. The identification of the larvae of African Simulium.
672. A survey of Simulium control in Africa.
673. A review of recent advances in scientific knowledge of the symptomatology, pathology and pathogenesis of onchoceral infections.
674. Entomological aspects of African onchocerciasis and observations on Simulium in the Sudan.
675. Onchocerciasis in the Sudan.
676. The identification of infective filarial larvae in Simuliidae.
677. Onchocerciasis presenting without dermatitis.
678. OCULAR ONCHOCERCIASIS IN NORTHERN GHANA: A TREATMENT SURVEY.
679. Aspects of black-fly control and entomology in the New World in relation to the Simulium problem in Nigeria.
680. Eye diseases in African children; with special reference to onchocerciasis and malnutrition.
681. The eradication of Simulium neavei from Kenya.
682. Posterior degenerative lesion of onchocerciasis.
683. Acute ocular onchocerciasis and its treatment.
684. Natural history of onchocerciasis.
685. Onchocerciasis and filariasis: Introduction.
686. Evaluation of new onchocercidal drugs used in Guatemala.
687. Resistance of Onchocerca volvulus microfilariae to diethylcarbamazine.
688. Notes and observations on onchocerciasis in Guatemala.
689. [Sandflies & onchocerciasis in Somaliland].
690. Simuliidae and their relation to onchocerciasis in the Sudan.
691. The pathogenicity of Onchocerca volvulus in relation to lymphadenopathy and elephantiasis.
692. Observations on the chemotherapy of onchocerciasis in Bahr el Ghazal Province, Sudan.
693. Simuliid vectors of onchocerciasis in Guatemala.
694. Bionomics of the vectors of onchocerciasis in the Ethiopian geographical region.
695. New observations on ocular onchocerciasis; related pathological methods and the pathogenesis of the various eye lesions.
696. Factors in the pathogenesis of ocular onchocerciasis.
697. ONCHOCERCIASIS.
698. Incidence of human infection with onchocerciasis in different communities in relation to the incidence and type of the ocular lesions.
699. Onchocerciasis.
700. A histological study of onchocerciasis treated with hetrazan.
701. Ocular onchocerciasis.
702. Onchocerca volvulus in Angola, Africa.
703. A case of onchocerciasis in London and its treatment with hetrazan.
704. Ocular Onchocerciasis in Guatemala. An Investigation of 1,215 Natives Infected With Onchocerca Volvulus.
705. OCULAR ONCHOCERCIASIS Including an Investigation in the Gold Coast.
706. Ocular Syndrome in Onchocerciasis.
707. Onchocerciasis.